Badge: Health
## Mental Health Monitoring Technology Lacks Robust Evidence, Experts Tell High-Profile Inquiry
**LONDON** – A high-profile inquiry investigating mental healthcare standards has heard concerning testimony regarding the widespread use of remote monitoring technology. Experts testifying before the Lampard Inquiry have stated that there is a “lack of robust evidence” to support the efficacy and safety of Oxevision, a system increasingly deployed in inpatient psychiatric settings.
Oxevision, an AI-powered camera system designed to monitor patients in mental health wards, is marketed as a tool to enhance patient safety by detecting early signs of distress, agitation, or self-harm risks through nocturnal and passive observation. Its developers claim it can alert staff to potential incidents, thereby reducing adverse events like falls or suicides.
The Lampard Inquiry, established to examine significant patient safety concerns within mental health services, has turned its attention to the technological solutions adopted by healthcare providers. During recent hearings, clinicians, researchers, and ethicists highlighted that despite its growing adoption, there is a conspicuous absence of independent, peer-reviewed clinical trials demonstrating Oxevision’s effectiveness in improving patient outcomes, reducing serious incidents, or proving its cost-effectiveness.
Critics expressed concerns that without rigorous evidence, healthcare trusts may be investing heavily in unproven technology, potentially diverting resources from other crucial patient interventions, such as increased staffing or direct therapeutic care. Moreover, questions of patient privacy, consent, and the potential for a ‘panopticon effect’ – where constant surveillance impacts patient well-being and autonomy – were also raised.
The testimony underscores a growing call for greater scrutiny and a robust evidence base for all new technologies introduced into sensitive healthcare environments, particularly those involving vulnerable patient populations. The Inquiry’s final recommendations are expected to address the ethical and clinical governance frameworks necessary for evaluating and deploying such innovations, ensuring that patient safety and well-being remain paramount.
